English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17326/19632 (88%)
Visitors : 3528872      Online Users : 42
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/28606

    標題: Inhibition of Tau Aggregation by Three Aspergillus nidulans Secondary Metabolites: 2,omega-Dihydroxyemodin, Asperthecin, and Asperbenzaldehyde
    作者: Paranjape, Smita R.
    Chiang, Yi-Ming
    Sanchez, James F.
    Entwistle, Ruth
    Wang, Clay C. C.
    Oakley, Berl R.
    Gamblin, T. Chris
    貢獻者: 藥學系
    關鍵字: tau
    microtubule-associated protein
    Aspergillus nidulans
    Alzheimers disease
    日期: 2014-01
    上傳時間: 2015-05-06 21:22:17 (UTC+8)
    出版者: Georg Thieme Verlag Kg
    摘要: The aggregation of the microtubule-associated protein tau is a significant event in many neurodegenerative diseases including Alzheimers disease. The inhibition or reversal of tau aggregation is therefore a potential therapeutic strategy for these diseases. Fungal natural products have proven to be a rich source of useful compounds having wide varieties of biological activity. We have screened Aspergillus nidulans secondary metabolites containing aromatic ring structures for their ability to inhibit tau aggregation in vitro using an arachidonic acid polymerization protocol and the previously identified aggregation inhibitor emodin as a positive control. While several compounds showed some activity, 2,-dihydroxyemodin, asperthecin, and asperbenzaldehyde were potent aggregation inhibitors as determined by both a filter trap assay and electron microscopy. In this study, these three compounds were stronger inhibitors than emodin, which has been shown in a prior study to inhibit the heparin induction of tau aggregation with an IC50 of 1-5 mu M. Additionally, 2,-dihydroxyemodin, asperthecin, and asperbenzaldehyde reduced, but did not block, tau stabilization of microtubules. 2,-Dihydroxyemodin and asperthecin have similar structures to previously identified tau aggregation inhibitors, while asperbenzaldehyde represents a new class of compounds with tau aggregation inhibitor activity. Asperbenzaldehyde can be readily modified into compounds with strong lipoxygenase inhibitor activity, suggesting that compounds derived from asperbenzaldehyde could have dual activity. Together, our data demonstrates the potential of 2,-dihydroxyemodin, asperthecin, and asperbenzaldehyde as lead compounds for further development as therapeutics to inhibit tau aggregation in Alzheimers disease and neurodegenerative tauopathies.
    關聯: Planta Medica, v.80 n.1, pp.77-85
    Appears in Collections:[藥學系(所)] 期刊論文

    Files in This Item:

    File Description SizeFormat

    All items in CNU IR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback